FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Kathiresan Sekar</u>					2. Issuer Name and Ticker or Trading Symbol Relay Therapeutics, Inc. [RLAY]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last)	(F	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/03/2024							Officer (below)	(give title	Other (below)	specify		
C/O RELAY THERAPEUTICS, INC. 399 BINNEY STREET, 2ND FLOOR						4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person					
(Street) CAMBRIDGE MA 02139					Form filed by More than One Re									than One Repo	rting		
(City) (State) (Zip)				F	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Та	ble I - Non-D	erivati	ve Se	ecurities	s Ac	quired, Di	sposed o	of, or Be	neficially	Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					action		Date,	Code (Instr.				Beneficia Owned Fo	s F Ily (ollowing (6. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code V	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)		(Instr. 4)			
			Table II - De (e.					uired, Dis , options,				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Code (Instr.		er of e s I (A) sed str. 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(5)			
Stock Option (Right to Buy)	\$6.79	06/03/2024		A		102,225		(1)	06/02/2034	Common Stock	102,225	\$0.00	102,225	D			

Explanation of Responses:

1. This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

/s/ Brian Adams, as Attorneyin-Fact

06/05/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.